Addex Therapeutics Ltd

Addex Therapeutics announced it has regained full global rights to all GABAB positive allosteric modulator assets discovered under its research collaboration with Indivior UK Limited. The return of rights follows Indivior's rationalization of its research and development activities and the planned merger of Indivior's parent company with Supernus Pharmaceuticals, Inc. The termination gives Addex full ownership of the returned development candidate, which was selected by Indivior for substance use disorders, and the freedom to pursue therapeutic indications beyond those originally contemplated under the agreement. Combined with Addex's wholly owned GABAB PAM program for chronic cough, the returned asset gives the company one of the broadest portfolios targeting GABAB receptor biology, with potential applications across substance use disorders, chronic cough, pain, overactive bladder, and neurodevelopmental disorders. CEO Tim Dyer said the company can now evaluate a range of strategic options, including seeking new partnerships in the near term or advancing the programs further before partnering.

Addex Therapeutics announced new preclinical research showing that its compound ADX71743, a selective negative allosteric modulator of mGlu7, significantly influences sleep-wake cycles and stress-related neurochemistry in animal models. The study, published in the International Journal of Neuropsychopharmacology, found that ADX71743 increased wakefulness while reducing both REM and non-REM sleep in rats, and altered stress-induced changes in neurotransmitters such as glutamate, GABA and monoamines across multiple brain regions. CEO Tim Dyer said the findings add important evidence supporting the therapeutic potential of targeting these receptors, and strengthen the rationale for Neurosterix's ongoing development of the mGlu7 program. ADX71743, discovered by Addex, has served as a prototype molecule in numerous publications exploring mGlu7's role in anxiety, stress, sleep, fear memory, and visceral pain. The program is now being advanced by Neurosterix, a neuroscience company launched by Addex and Perceptive Advisors in 2024.